NYSE : TAK

Takeda Pharmaceutical Company Limited

$17.24 USD

$0.42 (2.5%)

Volume
3.27M
Average Volume
3.22M
Market Capitalization
$54.85B
P/E Ratio
46.31
Dividend Yield
3.54%
Price Target
Year High
$18.90
Year Low
$12.99
Day High
—
Day Low
—
Payout Ratio
$1.63
Current Ratio
$1.27
Company Overview

NYSE

Julie So-Young Kim

Drug Manufacturers - Specialty & Generic

Healthcare

TAK

47029

JP

USD

https://www.takeda.com

81 3 3278 2111

874060205

0001395064

Liquidity Metrics

0.63

1.27

0.70

0.24

1.63

Sales & Valuation

$4.78T

1.99

1.14

11.48

250.35

Profitability

$63.91

$203.33B

4.26%

5.77%

2.61%

1.24%

P/E Metrics

46.31

0.60

0.60

Analyst Price Target & Rating

Neutral

3/5

6 Analysts

%

Financial Health Scores

1.27

7/9

$663.84B

$15.52T

$7.71T

$622.25B

Key Metrics (TTM)

$13.27T

2.95

9.76

1.27

2.61%

2.59%

2.17%

8.71%

$3706.31

249 days

Company Executives
Name Title
Christopher J. Morabito Head of R&D Pipeline Strategy
Christopher David O'Reilly Global Head of Investor Relations & Global Finance
Giles Platford President of International Business Unit
Milano Furuta Chief Financial Officer & Director
Salvatore Alesci Member of Management Board and Head of R&D Global Science & Biomedical Policy
Gabriele Ricci Chief Data & Technology Officer
So-Young Kim CEO, President & Director
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Michael Fox Chief Operating Officer
Haruhiko Hirate Member of Management Board
Iwaaki Taniguchi Senior Vice President of Corporate Finance & Controlling Department
Christophe Weber President, Chief Executive Officer & Representative Director
Andrew S. Plump President of Research & Development and Representative Director
Seigo Izumo Chair of Management Board
Poll Results

No votes yet today — be the first to share your view!

About Takeda Pharmaceutical Company Limited (NYSE:TAK) Stock

Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livt ... encity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.

Comparing Medicure (OTCMKTS:MCUJF) & Takeda Pharmaceutical (NYSE:TAK)

2026-07-26 01:59:11

Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and Medicure (OTCMKTS:MCUJF - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership. Analyst Ratings This is a breakdown of current recommendations

Takeda Pharmaceutical (TAK) to Announce Quarterly Earnings on Thursday

2026-07-23 02:27:12

Takeda Pharmaceutical (NYSE: TAK - Get Free Report) is anticipated to post its Q1 2027 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $0.1689 per share and revenue of $7.1469 billion for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2027 earning report for

Takeda's QDENGA becomes first dengue vaccine approved in India

2026-07-20 02:01:06

Japanese drugmaker ​Takeda Pharmaceutical's ‌dengue vaccine ​QDENGA ​has been approved ⁠by ​India's drug ​regulator, making it the ​first ​dengue vaccine to ‌be ⁠approved in the ​country, ​the ⁠company's Indian ​unit ​said ⁠on Monday.

Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials

2026-07-17 13:08:29

Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) on Friday revealed encouraging secondary data from two pivotal Phase 3 trials evaluating zasocitinib, its next-generation oral treatment for moderate-to-severe plaque psoriasis.

Takeda's Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

2026-07-16 18:00:00

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance acro.

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products

2026-07-12 19:00:00

OSAKA, Japan & CAMBRIDGE, Mass. & JAKARTA, Indonesia--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today announced a groundbreaking collaboration aimed at strengthening Indonesia's plasma ecosystem and supporting more equitable access to lifesaving plasma-derived medicinal products (PDMPs) in Indonesia and around the world. Marked by a.

Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery

2026-07-01 22:16:00

Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas.

Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million

2026-07-01 19:59:00

Takeda is set to pay InSilico to use its proprietary Pharma. AI platform to advance drug candidates across several therapeutic areas, according to people familiar with the matter.

Frequently Asked Questions

What is the current Takeda Pharmaceutical Company Limited (TAK) stock price?

Takeda Pharmaceutical Company Limited(NYSE:TAK) stock price is $17.24 in the last trading session. During the trading session, TAK stock reached the peak price of $18.9 while $12.99 was the lowest point it dropped to. The percentage change in TAK stock occurred in the recent session was 2.5% while the dollar amount for the price change in TAK stock was $0.42.

TAK's industry and sector of operation?

The NYSE listed TAK is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of TAK?

Christopher J. Morabito | Head of R&D Pipeline Strategy
Christopher David O'Reilly | Global Head of Investor Relations & Global Finance
Giles Platford | President of International Business Unit
Milano Furuta | Chief Financial Officer & Director
Salvatore Alesci | Member of Management Board and Head of R&D Global Science & Biomedical Policy

How many employees does TAK have?

Number of TAK employees currently stands at 47029. TAK operates from 1-1, Nihonbashi-Honcho 2-chome, Tokyo, OS 103-8668, JP.

Link for TAK official website?

Official Website of TAK is: https://www.takeda.com

How do I contact TAK?

TAK could be contacted at phone #81 3 3278 2111 and can also be accessed through its website. TAK operates from 1-1, Nihonbashi-Honcho 2-chome, Tokyo, OS 103-8668, JP.

How many shares of TAK are traded daily?

The average number of TAK shares traded daily for last 3 months was 3.22M.

What is the market cap of TAK currently?

The market value of TAK currently stands at $54.85B with its latest stock price at $17.24